483
Daito Pharmaceutical Co., Ltd.Daito Pharmaceutical Co., Ltd. – FDA 483, Jan 31, 2020
Record Details
The FDA inspection of Daito Pharmaceutical Co., Ltd. in Toyama, Japan, revealed significant deficiencies across laboratory controls, data integrity, equipment management, and quality systems. Repeated observations from a previous inspection indicate persistent issues with computerized system controls, supplier evaluation, and GMP documentation. The findings suggest a systemic lack of control over critical manufacturing processes and data.
View Company Profile
ID · 0e05b2e7-d007-44b8-82a3-763fe0ec6565
Other documents for Daito Pharmaceutical Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.